cancer

New technique is more streamlined and less expensive than current methods.

Chen is an assistant professor of chemical and biomolecular engineering at the UCLA Henry Samueli School of Engineering and Applied Science.

Findings could lead to better care planning and better outcomes for patients whose age puts them at higher risk

Findings shed light on why some head and neck cancers fare much worse after radiation therapy despite optimum treatment regimens.

The approach focuses on a protein called p53, which is commonly mutated in women who have high-grade serous ovarian cancer.

Researchers led by UCLA’s Dr. Edward Garon compared pembrolizumab to the chemotherapy drug docetaxel in a clinical trial involving more than 1,000 people.

The designation means that people with the disease will have greater access to the drug without first having to receive other treatments.

The findings could be an important step toward personalized medicine for women with the disease, said UCLA’s Dr. Patricia Ganz.

Of the 47 geographical areas the researchers analyzed, 20 had significantly higher percentages of people with advanced-stage disease than the U.S. norm.

Technique allows researchers to test many different small molecules at once.

The discovery could point the way toward new drugs that slow or stop the disease from spreading.

Less than 5 percent of men who chose to forgo aggressive treatment are being monitored as closely as they should be

Therapy targets not cancer cells but macrophages, a special type of immune cell, in order to prevent them from helping the cancer take root in the abdomen.

The therapy shows great promise for extending the lives of people with an advanced form of the disease, and it does so without causing a secondary skin cancer, a side effect seen in some patients who took only one of the drugs.

For the first time, researchers have described the cost throughout the entire treatment process — from the initial doctor’s visit to follow-up appointments.

Researchers say this research gives important insight into the cellular nature of aggressive prostate cancer, which will aid in the development of better treatments.

UCLA research had previously helped secure approval for Keytruda to treat advanced melanoma.

New program improves the likelihood that close relatives of colorectal cancer survivors will get screened for the disease, UCLA research shows.

The initiative will provide access to the latest therapeutic cancer clinical trials and state-of-the-art care for men and women who have served in the armed forces.

Participants in this month's 13th annual Avon Walk for Breast Cancer helped raise $600,000 for a UCLA Jonsson Comprehensive Cancer Center program to assist low-income or uninsured women with or at risk for the disease.

The findings could lead to better early detection of drug-resistant tumor cells and new therapies to suppress resistance as soon as therapy begins.

UCLA's Dribble for the Cure bounces into campus on Sunday, Oct. 11.

Other diagnostic tools may be more efficient and cost-effective for the general population, although genetic screening remains valuable for women in groups known to carry certain genetic mutations.

Method combines the chemotherapy drug decitabine with adoptive cell transfer, in which a patient’s own immune cells are reprogrammed to target brain cancer.

The sports network told the story of how Andrew Goldstein’s courageous story of coming out as gay to his college lacrosse teammates many years ago led to a friendship with a boy who contemplated suicide after coming out.